Company performance
Add to research
Current Price
as of Jun 13, 2025$124.39
P/E Ratio
42.18
Market Cap
$12.31B
Description
Add to research
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerNBIX
- Price$124.39-0.50%
Trading Information
- Market cap$12.31B
- Float96.47%
- Average Daily Volume (1m)981,537
- Average Daily Volume (3m)1,454,821
- EPS$3.04
Company
- Revenue$2.41B
- Rev growth (1yr)11.12%
- Net income$7.90M
- Gross margin98.39%
- EBITDA margin5.47%
- EBITDA$31.30M
- EV$10.89B
- EV/Revenue4.51
- P/E42.18
- P/S5.28
- P/B4.86
- Debt/Equity19.45
Documents
Add to research
SEC Filings
Factset Street Account